Future directions in the development of new antitubercular drugs. Where do we go from here?

Drugs and Aging

Volumn 10, Issue 6, 1997, Pages 405-410

  Yew, Wing Wai ^a   Chau, Chi Hung ^a  

^a GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (2,4,6 TRIMETHYLBENZYL) 1 PIPERAZINYL]RIFAMYCIN SV; AMINOGLYCOSIDE; CIPROFLOXACIN; CLOFAZIMINE; CYTOKINE; FCE 22807; LEVOFLOXACIN; MYCOBACTERIUM VACCINE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFALAZIL; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; SPARFLOXACIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

BACTERIAL CELL WALL; BACTERICIDAL ACTIVITY; BIOENGINEERING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; IMMUNOTHERAPY; MOLECULAR GENETICS; MYCOBACTERIUM; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

EID: 0030979556     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710060-00001     Document Type: Review

References (66)

1. Sudre P, ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992; 70: 149-59
2. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis inci-dence and mortality during 1990-2000. Bull World Health Organ 1994; 72: 213-20
3. WHO. Laboratory evaluation of drug resistant tuberculosis. Document WHO/TB/93.171. Geneva: WHO, 1993
4. WHO. WHO report on the tuberculosis epidemic 1995. Document WHO/TB/95.183. Geneva: WHO, 1995
5. Dickinson JM, Mitchison DA. In vitro properties of rifapentine (MDL 473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987; 68: 113-8
6. Dhillon J, Dickinson JM, Guy JA. Activity of two long-acting rifamycins, rifapentine and FCE 22807 in experimental murine tuberculosis. Tubercle Lung Dis 1992; 73: 116-23
7. Chan SL, Yew WW, Porter JHD, et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994; 3: 267-74
8. Tam CM. Clinical trial of rifapentine in Hong Kong [abstract]. Tubercle Lung Dis 1996; 77 Suppl. 2: S16
9. Gangadharam PRJ, Ashtekar DR, Farhi DC, et al. Sustained release of isoniazid in vivo from a single implant of biodegradable polymer. Tubercle 1991; 72: 115-22
10. Sensi P. Approaches to the development of new antituberculosis drugs. Rev Infect Dis 1989; 11 Suppl. 2: S467-70
11. Agarwal A, Kandpal H, Gupta HP. Tuftsin-bearing liposomes as rifampin vesicles in the treatment of tuberculosis in mice. Antimicrob Agents Chemother 1994; 38: 588-93
12. Mehta RT, Keyhani A, McQueen TJ. In vitro activities of free and liposomal drugs against Mycobacterium avium - M. intracellulare complex and M. tuberculosis. Antimicrob Agents Chemother 1993; 37: 2584-7
13. Rook GAW, Steele J, Ainsworth M, et al. Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology 1986; 59: 333-8
14. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074-81
15. Stanford JL, Grange JM. The promise of immunotherapy for tuberculosis. Respir Med 1994; 88: 3-7
16. Onyebujoh PC, Ahdulmumini T, Robinson S, et al. Immunotherapy with Mycobaterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med 1995; 89: 199-207
17. Davies PDO. Tuberculosis in the elderly. J Antimicrob Chemother 1994; 34 Suppl. A: S91-100
18. Thompson NP, Caplin ME, Hamilton MI, et al. Antituberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8: 1384-8
19. Yew WW, Lee J, Wong PC, et al. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in the presence of hepatic dysfunction. Int J Clin Pharm Res 1992; XII: 173-8
20. Kanyok TP, Reddy MV, Chinnaswamy J, et al. Activities of aminosidine (paromomycin) for Mycobacterium tuberculosis and Mycobacterium avium. J Antimicrob Chemother 1994; 33: 323-7
21. Kanyok TP, Reddy MV, Chinnaswamy J, et al. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob Agents Chemother 1994; 38: 170-3
22. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905-11
23. Young LS, Berlin OGW, Inderlied CG. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med 1987; 82 Suppl. 4A: S23-6
24. Rastogi N, Goh KS. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacteterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1991; 35: 1933-6
25. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, et al. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993; 37: 407-13
26. Yew WW, Piddock LJV, Li MSK, et al. In vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994; 34: 343-51
27. Yew WW, Kwan SYL, Ma WK, et al. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990; 26: 227-36
28. Kennedy N, Fox R, Kisyomhe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547-51
29. Willcox PA. Ofloxacin-based chemotherapy in multiple drug-resistant pulmonary tuberculosis. Drugs 1993; 45 Suppl. 3: S223-4
30. Schaherg T, Specht C, Stephan H. Use of sparfloxacin for treatment of multi-drug resistant pulmonary tuberculosis [abstract]. Tubercle Lung Dis 1995; 76 Suppl. 2: S86
31. Yew WW, Wong CF, Lee J. et al. Management of multidrug-resisiant tuberculosis (MDR TB): some experience from Hong Kong [abstract]. Chest 1996; 100 Suppl.: S128
32. Saito H, Sato K, Tomioka H, et al. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tubercle Lung Dis 1995; 76: 377-80
33. Mor N, Vanderkolk J, Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother 1994; 38: 1161-4
34. Klemens SP, Sharpe CA, Rogge MC, et al. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 1994; 38: 1476-9
35. Kennedy N, Fox R, Uiso L, et al. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother 1993; 32: 897-902
36. Berning SE, Madsen L, Iseman MD, et al. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med 1995; 151: 2006-9
37. Rastogi N, Ross BC, Dwyer B, et al. Emergence during unsuccessful chemotherapy of multidrug resistance in a strain of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1992; 11: 901-7
38. Cambau E, Sougakoff W, Besson M, et al. Selection of a gyr A mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170: 479-83
39. Dickinson JM, Mitchison DA. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68: 177-82
40. Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacteriuni tuberculosis. Am Rev Respir Dis 1990; 141: 626-30
41. Chan SL, Yew WW, Ma WK, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with tuberculosis. Tubercle Lung Dis 1992; 73: 33-8
42. Sirgel FA, Botha FJH, Parkin DP, et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother 1993; 32: 867-75
43. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, et al. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tubercle Lung Dis 1994; 75: 341-7
44. Schwander S, Rusch-Gerdes S, Mateega A. et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-associated tuberculosis: a single-blind randomized evaluation in Ugandan patients with HIV-infection and pulmonary tuberculosis. Tubercle Lung Dis 1995; 76: 210-8
45. O'Brien RJ, Lyle MA, Snider Jr DE. Rifabutin (ansamycin LM-427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 1987; 9: 519-30
46. Hong Kong Chest Service, British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tubercle Lung Dis 1992; 73: 59-67
47. Pretet S, Lebeaut A, Parrot R, et al. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant tuberculosis. Eur Respir J 1992; 5: 680-4
48. Hirata T, Saito H, Tomioka H, et al. In vitro and in vivo activities of the benzoxazino-rifamycin, KRM-1648, against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2295-303
49. Jagannath C, Reddy MV, Kailasam S, et al. Therapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular and in vivo studies. Am J Respir Crit Care Med 1995; 151: 1083-6
50. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989; 33: 1493-9
51. Rastogi N, Frehel C, Ryter A, et al. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for the exclusion of the antimicrobial agents? Antimicrob Agents Chemother 1981; 20: 666-77
52. Rastogi N, Goh KS, David HL. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother 1990; 34: 759-64
53. Heifets LB, Iseman MD, Lindholm-Levy PJ. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex: bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis 1988; 137: 711-5
54. 2. J Am Chem Soc 1983; 105: 240-5
55. Cynamon MH, Palmer GS. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983; 24: 429-31
56. Yew WW, Wong CF, Lee J, et al. Do beta-lactam-beta-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant tuberculosis? Tubercle Lung Dis 1995; 76: 90-2
57. Zhang Y, Lathigra R, Garbe T, et al. Genetic analysis of superoxide dismutase, the 23 kilodalton antigen of Mycobacterium tubercolosis. Mol Microbiol 1991; 5: 381-91
58. Beaman L, Beaman BL. Monoclonal antibodies demonstrate that superoxide dismutase contributes to protection of Nocardia asteroides within the intact host. Infect Immun 1990; 58: 3122-8
59. Jacobs WR, Barletta RG, Udani R, et al. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science 1993; 260: 819-22
60. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-50
61. Zhang Y, Heym B, Allen B, et al. The calalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-3
62. Zhang Y, Young DB. Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. Trends Microbiol 1993; 1: 109-13
63. Banerjee A, Dubnau E, Quemard A, et al. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-30
64. Bodmer T, Zurcher G, Imboden P, et al. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995; 35: 345-8
65. Moghazeh SL, Pan X, Arain T, et al. Comparable antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoβ mutations. Antimicrob Agents Chemother 1996; 40: 2655-7
66. Cole ST. Why sequence the genome of Mycobacterium tuberculosis? Tubercle Lung Dis 1996; 77: 486-90